The Register-Herald, Beckley, West Virginia

January 9, 2014

Our Readers Speak — Thursday, January 9, 2013

— As we approach the 2014 legislative session, the prescription status of pseudoephedrine is again being debated. It is imperative the medical community lend its voice to the debate to ensure this decision is based on the facts.

This initiative has been side-tracked by a mirage of public outcry and economic shell games that do not take into account the societal costs of methamphetamine abuse and addiction.

Pseudoephedrine is one of two oral decongestants indicated for the temporary relief of nasal congestion. It is not a curative medication. It does not reduce the duration of any illness and does not prevent any long-term complications.

Pseudoephedrine has many contraindications and side effects. It is relatively contra-indicated in patients with hypertension. It should be used with caution in patients with heart disease, cerebrovascular disease, diabetes, hyperthyroidism, glaucoma and prostatic enlargement.

Pseudoephedrine is also the only essential ingredient in the manufacturing of methamphetamine. The manufacturing process utilizes toxic and flammable materials. This process endangers those around the manufacturing process and those who are forced to deal with the toxins left behind. This group includes innocent children and our first responders.

Recent efforts to limit pseudoephedrine availability have done nothing to curtail the manufacturing of methamphetamine. Lab seizures increased with recent law changes. The states that have enacted “prescription only” laws have seen a dramatic decrease in methamphetamine production.

I had the opportunity to participate with the Kanawha County Drug Task Force. This group, consisting of pharmacists, physicians, educators, law enforcement and business representatives, was overwhelmingly in favor of making pseudoephedrine prescription only, except for tamper resistant products. This is the same recommendation provided by the governor’s task force.

Arguments against this policy change center around mythical public sentiment and economics. I have yet to have one patient voice concern about a change. The economic arguments do not take in to account the costs of cleanup, law enforcement and the societal costs of addiction. Further, the exemption of tamper resistant products still allows for nonprescription access for these products.

Drug abuse and addiction are at epidemic levels in this state and this country. This is one of many steps that need to be taken to turn this epidemic around. This is an easy and necessary step to curb this growing problem. Time is no longer on our side. Action needs to be taken now.

Bradley Henry

M.D.; B.S. Pharmacy